T. G. P. Grunewald

This study identifies how the EWS::FLI1-DHX9 interaction influences R-loop metabolism and Ewing sarcoma sensitivity to DNA topoisomerase 1 inhibitors.

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

This study shows FAK promotes migration and prevents apoptosis in Ewing sarcoma via Y397 phosphorylation, suggesting FAK inhibitors could target metastasis.

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.